Wim J.G. Oyen - Selected Publications#

> 650 peer reviewed papers and reviews
H-index Google Scholar 111 (citations 49,800; i10-index 569)

Herrmann K, Krause BJ, Hadaschik B, Kunikowska J, van Poppel H, N´Dow J, Sartor O, Oyen WJG. Nuclear medicine theranostics comes of age. Lancet Oncology 2021; 22: 1497-1498.

Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija, G Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncology 2021; 22: e136-e172.

Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Amyloid-PET and 18 F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology 2020; 19: 951-962.

Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen WJG, de Bono JS. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. European Urology 2019; 76: 469-478.

de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, Morreau H, Schepers A, Smit J, Oyen WJG, Vriens D. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocrine Reviews 2018; 2018; 39: 154-191.

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG, Mulders PFA. PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. European Urology 2018; 74: 257-260.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O’Sullivan JM, Padhani AR, Schalken J, Scher HI, Tombal B, van Moorselaar JA, van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology 2018; 19: e696-e708.

Grootjans W, de Geus-Oei LF, Troost E, Visser E, Oyen WJG, Bussink J. PET in the management of locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology 2015; 12: 395-407.

Aarntzen EHJG, Srinivas M, Jacobs JFM, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, Rossum MM, Boerman OC, Punt CJA, Figdor CG, Oyen WJG, de Vries IJM. Early identification of antigen-specific immune responses in vivo by [18F]]FLT PET imaging. Proceedings of the National Academy of Sciences 2011; 108: 18396-18399.

Bussink J, Kaanders JHAM, van der Graaf WTA, Oyen WJG. PET-CT for radiotherapy treatment planning and therapy response monitoring in solid tumors. Nature Reviews Clinical Oncology 2011; 8: 233-242.